Literature DB >> 10646045

Racecadotril demonstrates intestinal antisecretory activity in vivo.

M P Primi1, L Bueno, P Baumer, H Berard, J M Lecomte.   

Abstract

BACKGROUND: Racecadotril (acetorphan), a potent enkephalinase inhibitor, protects endogenous enkephalins from degradation. Racecadotril exhibits experimental and clinical antidiarrhoeal activity without any effect on intestinal motility, suggesting selective antisecretory activity. The antisecretory effect of racecadotril was directly assessed in the present study.
METHODS: A 1 m, jejunal, Thiry-Vella loop was created in six mongrel dogs, and water and ionic fluxes were evaluated during infusion (2 mL/min) of Tyrode solution labelled with 14C-polyethylene glycol. Fluxes were determined both in the basal state and 5-6 h after commencement of a 2-h infusion of cholera toxin (0.4 microgram/mL). Racecadotril (10 mg/kg) or vehicle was given orally with and without prior intravenous administration of naloxone (0.1 mg/kg) or phentolamine (0.2 mg/kg).
RESULTS: Basal absorption remained unchanged following racecadotril administration; however, racecadotril significantly decreased (P = 0.01) cholera toxin-induced water, sodium, and potassium hypersecretion, from 0.73 +/- 0.15 to 0.37 +/- 0.13 mL/min; from 125.0 +/- 16.1 to 14.7 +/- 9.5 microMol/min; and from 3.41 +/- 0.66 to 1.66 +/- 0.61 microMol/min, respectively. This antisecretory activity of racecadotril was suppressed by naloxone but not by phentolamine.
CONCLUSIONS: This study directly demonstrates the antisecretory activity of racecadotril in relation to the protection of endogenous enkephalins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10646045     DOI: 10.1046/j.1365-2036.13.s6.3.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

Review 1.  Novel targets for the control of secretory diarrhoea.

Authors:  M J G Farthing
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Racecadotril.

Authors:  A J Matheson; S Noble
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults.

Authors:  Hwang-Huei Wang; Ming-Jium Shieh; Kuan-Fu Liao
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 4.  Treatment of infectious diarrhea in children.

Authors:  Nure H Alam; Hasan Ashraf
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

6.  Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial.

Authors:  N H Alam; H Ashraf; W A Khan; M M Karim; G J Fuchs
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 7.  Rotavirus infection.

Authors:  Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes
Journal:  Nat Rev Dis Primers       Date:  2017-11-09       Impact factor: 52.329

8.  ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults.

Authors:  Mark S Riddle; Herbert L DuPont; Bradley A Connor
Journal:  Am J Gastroenterol       Date:  2016-04-12       Impact factor: 10.864

9.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

Review 10.  Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.

Authors:  Marta Sobczak; Maciej Sałaga; Martin A Storr; Jakub Fichna
Journal:  J Gastroenterol       Date:  2013-02-09       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.